Human U251MG glioma cells expressing the membrane form of macrophage colony-stimulating factor (mM-CSF) are killed by human monocytes in vitro and are rejected within immunodeficient mice via paraptosis that is associated with increased expression of three different heat shock proteins Martin R Jadus, Human U251MG glioma cells retrovirally transduced with the human gene for the membrane form of macrophage colonystimulating factor (mM-CSF) were investigated. The clones, MG-2F11 and MG-2C4, that expressed the most mM-CSF, but not the viral vector or the parental U251MG cells, were killed by both murine and human monocyte/macrophages in cytotoxicity assays. MG-2F11 cells failed to form subcutaneous tumors in either nude or NIH-bg-nu-xidBR mice, while mice inoculated with the U251MG viral vector (MG-VV) cells developed tumors. Electron microscopy studies showed that 4 hours after subcutaneous injection, the mM-CSF-transduced cells began dying of a process that resembled paraptosis. The dying tumor cells were swollen and had extensive vacuolization of their mitochondria and endoplasm reticulum. This killing process was complete within 24 hours. Macrophage-like cells were immediately adjacent to the killed MG-2F11 cells. Immunohistological staining for the heat shock proteins HSP60, HSP70 and GRP94 (gp96) showed that 18 hours after inoculation into nude mice, the MG-2F11 injection site was two to four times more intensely stained than the MG-VV cells. This study shows that human gliomas transduced with mM-CSF have the potential to be used as a safe live tumor cell vaccine.
very year approximately 17,000 new patients are diagnosed within the United States with glioblastoma multiforme. 1 These high-grade gliomas recur after surgical resection with standard chemo-and radiation therapies. The prognosis of these patients is still extremely poor. 2, 3 Several immunotherapy approaches have included the following: administering immune adjuvants, antiglioma and growth factor receptor-specific antibodies, cytokine transduced glioma cell vaccines and ex vivo stimulated tumor infiltrating lymphocytes (TIL) and lymphokine-activated killer cells (LAK). [4] [5] [6] [7] [8] [9] [10] These immunotherapeutic modalities occasionally cured a few patients. These positive responses have encouraged further research into methods to generate better immune responses so that more glioma patients may be treated using immuno-based methods.
Various proinflammatory cytokines (interleukin 2, 4, 6, 7, 12, IFN-g, granulocyte-macrophage colony-stimulating factor (GM-CSF)) have proved useful in prophylactic vaccination against rodent gliomas.
11-18 Both CD4+ and CD8+T-cell responses were generated and produced immunity against the rechallenge of parental tumors. Parney et al 19 transduced the human D54MG glioblastoma cell line in vitro with genes encoding GM-CSF and the T-cell costimulatory molecule B7-2. When SCID/beige mice were reconstituted with human PBL, these ''humanized'' mice then inhibited the growth of these dual transduced tumors. Although these tumors still grew at a much slower rate, it suggested that the human effector cells were actively mounting an immune response against the tumor cells in vivo. The best vaccination occurred when the tumor cells were transduced with both the GM-CSF and B7-2 genes. These studies indicate that it is possible to induce a human antiglioma immune response using gene-modified human glioma cells in a complex in vivo setting without risking patient safety.
Previously, we have shown that malignant rat T9 glioma tumor cells transduced with mM-CSF, but not the secreted form of M-CSF, are directly killed by macrophages in vitro through an mM-CSF dose-dependent pathway that relied upon phagocytosis of the transduced tumor cells. 20, 21 Not only were these mM-CSF expressing T9 tumor cells rejected, but concurrently a strong T-cellmediated immunity was induced that was capable of rejecting an intracranial T9 glioma. 22, 23 Our studies show that immune responses induced by mM-CSF-transduced cells is quite similar to tumor cells cotransduced with both the GM-CSF and B7-2 genes. Besides being able to vaccinate rats against this tumor, rats bearing small 1-3 day established intracranial T9 glioma could be successfully treated 93-83% of the time by a peripheral vaccination with mM-CSF expressing tumor cells. 24 Immunization with living mM-CSF T9 tumor cells stimulated cross-protective immunity that resisted different syngeneic RT2 and F98 gliomas. 21 This type of crossprotective resistance has not been reported with other cytokine transfection tumor models.
Our animal data using the mM-CSF-transduced rat gliomas is promising, but it does not guarantee that the mM-CSF expressing human glioma cells will provoke identical types of immune responses. This study shows that mM-CSF-transduced human glioblastoma cells are killed by both murine and human monocytes/macrophages in vitro. In vivo studies using immunodeficient mice showed that these transfected tumor cells are infiltrated by monocytes/macrophages within 4 hours. At this time the tumor cells start to be killed via a process that resembles paraptosis that is independent of phagocytosis. As a result of this killing, tumors will not form in either nude or NIH-bg-nu-xid mice. After 18 hours of the implantation of the mM-CSF-transfected cells, these tumor cells expressed three different forms of the heat shock proteins, HSP60, HSP70, GRP94(gp96). These induced proteins have been associated with the induction of tumor immunity in several tumor models and could help explain why mM-CSF-transfected tumor cells function as immunogens. We have demonstrated that mM-CSF-transfected tumor cells also produce immunoprotection in a weakly immunogenic MADB106 breast cancer model 25 and a nonimmunogenic Hepal-6 liver cancer model. 26 This study suggests that mM-CSFtransfected human glioma cells can be used as a safe tumor vaccine and may have immunizing properties, which are not seen when prekilled tumor cells or dendritic cells pulsed with tumor-derived antigenic peptides are used as the vaccine.
Materials and methods

Cell lines and cell culture
The human U251MG glioma cell line was obtained from Dr Dennis Deen (University of California, San Francisco).
The cells were propagated in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS, Gemini BioProducts, Calabassas, CA), with antibiotics in a humidified atmosphere of 5% CO 2 at 371C. All culture supplies were screened and selected on the basis of being endotoxin-free (under the limits of detection by limulus amebeocyte lysate assay). Cells were determined to be mycoplasma free, based on Strategene's mycoplasma PCR analysis kit (Strategene Inc., San Diego, CA).
Transfection of mM-CSF gene and viral vector into tumor cells
The U251MG cells were infected in six-well cluster dishes (Corning, Corning, NY). A total of 100,000 exponentially growing cells were incubated either in the presence or absence of the supernates of the mM-CSF-or viral vectortransducing retroviruses overnight. The cells were refed with fresh media containing 1 mg/mL G418. After 2 weeks of G418 selection, the cells were cloned by limiting dilution in 96-well microtiter plates. For mM-CSF detection, cells were tested by flow cytometric analysis as described below.
Antibodies and flow cytometry
Tumor cells were incubated with the anti-M-CSF antibody or normal goat serum on ice for 1 hour. Goat antihuman M-CSF antibody was purchased from R&D Systems (Minneapolis, MN). Human monocytes were identified by incubating the cells on ice with the antihuman CD64 antibody (mouse IgG) purchased from Pharmingen (San Diego, CA). The cells were washed once with ice-cold PBS in a refrigerated centrifuge and then incubated in a 1:10 dilution of a fluorescein isothiocyanate (FITC)-labeled rabbit antiprimary antibody (Vector Laboratories, Burlingame, CA) for an additional hour on ice. The cells were washed three times in cold PBS. A total of 10,000 cells were analyzed on the flow cytometer. Data were analyzed by Multi2D (Phoenix Flow Systems, San Diego, CA).
Bone marrow-derived macrophage cultures
Mouse bone marrow cells were cultured in RPMI-1640 media (Life Technologies, Grand Island, NY) containing 5% FBS and M-CSF supernate derived from mM-CSFtransfected T9-C2 cells. 20 After 1 week of culture at 371C in a humidified, 5% CO 2 atmosphere, the media were replaced with fresh 33% conditioned media every 3-4 days. Macrophages were removed by washing off the tissue culture media and then incubating the cells in phosphate-buffered saline (PBS) for at least 30 minutes to 1 hour at 41C. The cells were dislodged using a cell scraper. This procedure results in 495% viability of the macrophages, which were phenotyped being 490% positive for Mac 1, Mac 2, Mac 3 and F4/80.
Human effector cells
After signing informed consent, human donors' peripheral blood mononuclear cells from cancer patients /ml. Before starting the cytotoxicity study, the viability of the thawed PBMC was examined by trypan blue exclusion and was 490%.
Plastic Petri dishes were overlayed with 2 ml FBS and incubated for 15 minutes at 371C. The FBS was aspirated and the dishes were used immediately. The cryopreserved human PBL cells were thawed out and resuspended at 3-5 Â 10 6 cells/ml in RPMI-1640 media supplemented with 10% FBS. The cell suspension was added to the FBSpretreated dishes (5 ml/dish) and incubated at 371C for 1 hour. The dishes were gently washed three times with PBS. The adherent cells were detached using 5 ml of versene buffer (Life Technologies). The remaining adherent cells were dislodged using a cell scraper after 1 ml of FCS was added to the versene.
HLA tissue typing of U251MG glioma cell line
The U251MG cells were tissue typed for MHC class I by PCR techniques by Dr Robertson Parkman, Children's Hospital of Los Angeles, Department of Research Immunology and Bone Marrow Transplantation (Los Angeles, CA). These cells were identified as HLA-A2+, B18+, Bw6+ and C5+.
Cytotoxicity studies
Human and mouse macrophage-medicated cytotoxicity studies were performed according to our previously used methods. 20, 21 Exponentially growing tumor cells in 10 ml of complete media were internally labeled with 10 mCi of 3 H-thymidine ( 3 H-TdR) (ICN, Costa Mesa, CA) overnight. The tissue culture media were replaced with fresh media and allowed to incubate a further 1-3 hours to reduce spontaneous release by the tumor cells. A total of 10,000 target cells were incubated in 200 ml of media with graded doses of monocytes/macrophages ranging from 20:1 to 2.5:1 at 371C in a humidified 5% CO 2 incubator for 24-48 hours. Afterward, 100 ml of supernatant was removed and placed in 2 ml of scintillation fluid. Maximum release is calculated by taking 10 4 target cells and rapidly freeze-thawing them three times in liquid nitrogen. Specific release is calculated using the standard equation for cytotoxicity reactions:
Cytotoxicity data from triplicate cultures at each macrophage : tumor cells ratios are presented as the mean 7SD. Cytotoxicity is not considered relevant if values are less than 10% specific killing. Data from the cytotoxicity assays were analyzed using Student's t-test. Values were considered significantly different at the Po.05 levels.
Tumor growth in animals
Animal use was carried out according to the Animal Studies Committee approved protocols. Nude (Crl:nu/ nu-nuBR) mice and NIH-bg-nu-xidBR (SCID/biege/ xid) mice were obtained from Charles River (Wilmington, MA). The animals were housed in our AAALAC accredited facility. The immunodeficient mice were housed in sterile microisolators. Manually restrained mice were injected subcutaneously on the ventral side with 3 Â 10 5 -10 6 cells in a volume of 50 ml. After 5-7 days, when the tumors were palpable they were measured with metric calipers according to the length, width and height of the tumor three times a week. The tumor volume was then calculated by the equation: volume ¼ length Â width Â height Â p/6. The data are expressed as the mean tumor volume7SEM. Data at each time point were then compared using a Student's t-test. A P-value o.05 was considered significant.
Electron microscopic studies
The mice were injected with 5 Â 10 6 cells resuspended in 50 ml PBS on the ventral side. Tissues taken at 4 hours postinjection were fixed for 1-2 hours with 2.5% glutaraldehyde at pH 7.3 in 0.1 M Sorensen's phosphate buffer. The tissues were then rinsed in Sorensen's buffer, postfixed for 1 hour in 1% OsO 4 , and rinsed again in Sorensen's buffer. Following dehydration with a cold graded ethanol series and subsequent transfer to propylene oxide, the tissues were infiltrated with Spurr's resin over a period of 36 hours. Sections taken with a diamond knife were stained with uranyl acetate and lead citrate and then observed using a JEOL-1200EX II transmission electron microscope (Peabody, MA).
Immunohistology
At 4-18 hours after subcutaneous inoculation in nude mice, the MG-2F11 and U251MG-VV tumors were removed and sectioned in a cryostat. The rabbit antiheat shock protein-70 antibody was obtained from Chemicon Intl (Temecula, CA). Rabbit antiheat shock protein-60 and anti-GRP94 (also known as gp96) antibodies were purchased from Stress Gen (Victoria, BC, Canada). The antibodies were diluted 1:100 in PBS. The tissue was incubated 2 hours with the primary antibody in a humidified chamber at 41C. The slides were washed three times in PBS and the 1:100 diluted biotinylated goat antiprimary antibody (Pharmingen Inc., San Diego, CA) was incubated at room temperature for 30 minutes. The slides were washed three times in PBS and incubated for 30 minutes in the streptavidin conjugated peroxidase (DAKO Inc., Carpinteria, CA). The tissue was rinsed three times in PBS and then the DAB substrate (DAKO) was added. The tissue was briefly counterstained in freshly filtered Mayer's hematoxylin (DAKO) for 15 seconds and then mounted with a cover slide using Vector's Laboratories Mounting Media (Burlingame, CA). The staining of the cells was then scored by at least two people using a multiheaded microscope. Scoring was assessed by staining intensity and the total number of cells positively stained above the negative controls.
Results
mM-CSF transduction of the U251MG cells
The human U251MG cells were transduced using retroviral vectors as previously described. 20 Once the cells were positively selected with G418, they were cloned by the limiting dilution method. Three dozen clones were analyzed by flow cytometry for the expression of mM-CSF. The two best expressing clones, MG-2F11 and MG-2C4, were selected for further use (Fig 1) . The MG-2F11 cells are roughly four times as fluorescent as the MG-2C4 cells. The expression of mM-CSF on these cells has remained stable over the last 3 years. The parental U251MG cells transduced with an empty viral vector control retrovirus (MG-viral vectors) and were negative for mM-CSF expression (data not shown).
Mouse macrophages kill the mM-CSF-transfected human glioma cells
Initial cytotoxicity experiments were performed with mouse bone marrow-derived macrophages since these cells were readily available at the time these mM-CSFtransduced clones were being characterized. The mouse macrophages killed the MG-2F11 and MG-2C4 cells, but not MG parental cells or MG-viral vector cells in two separate cytotoxicity assays (Fig 2) . At macrophage to tumor ratios from 2.5:1 to 10:1, the macrophages killed the MG-2F11 glioma cells in a dose-dependent manner. The difference in killing between the two mM-CSFtransduced cell lines was significantly different (Po.05) from the parental U251MG cells and MG-viral vector cells. These data show that the mM-CSF-transduced clones are killed by mouse macrophages. Since the MG-2F11 cells had more mM-CSF than the MG-2C4 cells and were killed by the macrophages, we chose to use this clone for all further work.
Human PBMC and monocyte/macrophages can kill the mM-CSF-transfected human glioma cells Human PBMC from several HLA-A2-matched individuals were tested for their cytotoxicity towards the To show that the human monocytes/macrophages were killing the mM-CSF-transduced cells, we enriched the monocytes by adherence to plastic culture dishes. The adherent cells proved to be positive (495%) for the monocyte/macrophage marker CD64. These adherent monocytes were tested in cytotoxicity assays towards MG-2F11 and MG parental cells. A representative experiment performed with two separate donors in two independent experiments showed that the MG-2F11 cells were killed in a dose-dependent manner. Aliquots of these same monocytes failed to kill the MG parental cells when tested in simultaneous parallel studies (Fig 3b) .
mM-CSF-transfected U251MG cells did not grow in subcutaneous sites in immunodeficient mice
Nude and NIH-bg-nu-xidBR mice were implanted subcutaneously with 3 Â 10 5 MG-VV or MG-2F11 cells on day 0. Mice implanted with the MG-VV control cells formed tumors within 3 weeks in seven out of eight with both nude (Fig 4a) and NIH-bg-nu-xidBR (Fig 4b) mice. These tumors grew consistently until the animals were euthanized. All of the eight nude mice that received an equivalent dose of MG-2F11 cells failed to form tumors. All eight NIH-bg-nu-xidBR mice failed to form MG-2F11 tumors during the first 50 days after inoculation (Fig 4b) . One NIH-bg-nu-xidBR mouse eventually formed the MG-2F11 tumor three months after inoculation. The other seven mice remained tumor free. The growth difference between the MG-VV and MG-2F11 tumors in nude and NIH-bg-nu-xidBR mice was statistically significant (Po.01) beginning on day 33 for the nude mice and day 38 for the NIH-bg-nu-xid mice.
The nude mice that rejected the MG-2F11 cells were then rechallenged with the MG-VV cells to determine whether immunity was induced. All of the eight mice that rejected the MG-2F11 clone failed to resist the growth of the U251MG parental cells (data not shown), demonstrating that there was no inherent immunological memory stimulated in these immunocompromised mice against the U251MG tumor cells.
To show that the MG-2F11 cells could form tumors in mice, we pretreated NIH-bg-nu-xidBR mice with Immunodeficient mice reject human gliomas making mM-CSF MR Jadus et al anti-asialo GM1 antibody. Previously, it was shown that this antibody could deplete mice of their NK cells, activated T cells and activated macrophages. 27, 28 Since the NIH-bg-nu-xidBR mice lack NK and T cells, this antibody will deplete the activated macrophages. Even when 3.3 times more MG-2F11 cells (10 6 cells) were injected into these immunodeficient mice, none of the control mice developed a tumor, while four out of five mice pretreated with the anti-asialo GM1 antibody formed the MG-2F11 tumor (Fig 4c) . The mice pretreated with the anti-asialo GM1 antibody allowed the MG-VV tumors to grow as well (data not shown).
Electron microscopy indicates that the MG-2F11 cells were killed by a process that resembles paraptosis
Electron microscopy was used to study the mechanism through which the tumor cells were being eliminated. Studies showed that after implantation of the MG-2F11 cells, there was no evidence that the tumor cells were growing; that is mitotic figures and cell division. Figure 5a demonstrates that the MG-2F11 cells displayed a swollen phenotype 4 hours after being injected subcutaneously. The type of cell death that best describes these dying tumor cells is called paraptosis. 29 Swelling of the cells was evident as a loss of electron-dense material. Macrophagelike cells were found to be adjacent to the dying tumor cells. Most of the MG-2F11 cells were swollen, and vacuolated with rare membrane blebbing (zeiosis), while the viral vector control cells never appeared this way. The MG-2F11 cells had some areas of condensed nuclear chromatin, but these dying tumor cells rarely formed smaller apoptotic bodies. One notable feature was that the mM-CSF-transfected tumor cells were not killed by direct phagocytosis.
During the course of these studies the macrophages did show signs of activity that resulted in morphological changes. Normal monocytes/macrophages were more electron dense than the tumor cells. As the macrophages became activated, they appeared to become more heavily electron dense. Some activated macrophages showed signs of becoming apoptotic by membrane blebbing and cellular break-up (Fig 5b) .
Immunohistochemical staining of the MG-2F11 injection site reveals enhanced heat shock protein staining
The results of the electron microscopy suggested that nonphagocytic cytotoxic functions of the macrophages were being induced by the mM-CSF-transfected U251MG cells. Cells dying of necrosis have been demonstrated to display increased amounts of the various heat shock proteins (HSP). 30 Since little is known of cells dying of paraptosis, we analyzed these dying tumor cells for the production of the heat shock proteins. Tumor sections were then stained for three different members of this diverse family of HSPs (HSP60, HSP70 and GRP94). When the tissue was examined after 4 hours, neither the MG-2F11 tumor nor the MG-viral vector (MG-VV) tumor displayed any significant amount of HSP (data not shown). However, when we assayed the tumor sites after 18 hours, the MG-2F11 tissue proved to be 2-4 times more strongly positive for the HSP60 (Fig 6b) , HSP70 (Fig 6c) and GRP94(gp96) (Fig 6d) than the MG-VV tumor. The immunohistology showed that HSP70 and GRP94(gp96) staining was four times more intense than that seen with the MG-VV. HSP60 staining was only twice the intensity seen with the MG-viral vector cells. The kinetics of this reaction suggests that this paraptotic killing of the mM-CSF expressing MG-2F11 cells does appear to produce a multiple heat shock protein response.
Discussion
Our previous experience using the rat T9 glioma cells, also known as 9L, transduced with mM-CSF showed that tumor rejection and subsequent immunity against the parental tumor occurs in vivo. The immunity that was produced by the therapeutic vaccination could even protect rats with small 1-4-day-old established intracranial tumors. 24 These last results were comparable or even better than those reported by Okada, et al 17 when they ran identical studies using IL-4 transfected 9L cells as the subcutaneous tumor vaccine to treat 3-day-old established intracranial 9L gliomas. We have seen that the immunity induced by vaccinating with these mM-CSF-transfected T9-C2 cells could also immunize rats against other syngeneic RT2 and F98 gliomas. These unique findings in the rat glioma model encouraged us to investigate whether human mM-CSF-transduced gliomas could behave in a similar manner in the hope of developing these cells into an allogeneic human tumor vaccine.
In the present study, we report that the human U251MG glioma upon transfection with mM-CSF was killed in vitro by mouse macrophages. HLA-A2-matched human PBL and the enriched human monocytes/macrophages also killed these tumor cells in vitro. We observed that the best killing by PBL occurred at a ratio of 100:1, when the highest effector : target ratio was used. We speculate that this ratio had the optimal number of monocytes present to kill the mM-CSF-transduced MG-2F11 tumor cells, since the PBMC only contain 3-5% monocytes. When we enriched for monocytes, the optimal killing of the MG-2F11 cells was at a ratio of 20:1 and 10:1. No killing was observed against the MG parental cells at these same monocyte : tumor ratios. This is the first time that our lab has shown that human monocytes/ macrophages can kill mM-CSF-transduced human tumor cells, suggesting that our previous work in the rodent models can be directly translatable with human tumors.
In vivo studies showed significantly reduced tumorigenicity of the MG-2F11 tumor in immunodeficient mice when compared to viral vector control U251MG cells. In both nude mice (all eight tested, 0% with tumors) and NIH-bg-nu-xidBR mice (one out of eight mice, 13% with tumors) failed to show growth of subcutaneous inoculated MG-2F11 cells, while the viral vector control cells grew in the immunodeficient mice. When NIH-bg-nu-xidBR mice were pretreated with anti-asialo GM1 antibody, which depletes the activated murine macrophages, the MG-2F11 glioma cells formed tumors in four out of five mice. This work demonstrates that macrophages actively inhibited the growth of the mM-CSF-transfected U251MG gliomas.
The mechanism through which the macrophages killed the tumor cells resembled a newly described process called paraptosis. 29 Paraptosis is a form of programmed cell death that differs from apoptosis. As a result of an insult delivered by the macrophages, the tumor cells began a swelling and vacuolization process that is associated with disruption of the endoplasmic reticulum and mitochondria. In contrast, apoptosis is characterized by cell shrinkage and membrane blebbing that culminates in apoptotic body formation. Immunohistology revealed that the tumor site had the increased expression of three different members of the HSP family of proteins. This suggests that the tumor cells produced the HSP to counteract the attack delivered by the macrophages. Relatively little is known of the immunological vaccinating properties of paraptotic tumor cells. Using the rat T9 tumor model, we have seen that both PMNs and macrophages contributed to the paraptotic killing of the mM-CSF-expressing T9-C2 cells. 31 However in this study, we have only observed a monocytic/macrophagic infiltrate within the implanted MG-2F11 cells. Thus, human tumor cells can be killed via paraptosis by only monocytes/macrophages.
Cells that die of apoptosis usually do not provoke immunological responses, although apoptotic cells can be used to stimulate antitumor immunity with the help of in vitro cultured dendritic cells. Cells that are killed via a necrotic pathway tend to become more immunogenic when directly compared to apoptotic cells. [32] [33] [34] [35] [36] [37] This key feature is perhaps the basis of the ''Danger Hypothesis''. 38 Released HSPs may be a key component, which alerts the immune system of potential dangers elicited by necrotic cells. Necrotic cells will produce heat shock proteins. 30, 36 HSPs have been described as ''natural adjuvants'' since they provoke immunity. 35 In this regard, paraptotic cells resemble necrotic cells. Three different members of this diverse family of proteins (HSP60, HSP70 and GRP94) were expressed in the paraptotic MG-2F11 cells. In some tumors, HSP70 and gp96 have been identified as tumorspecific antigens. 39 In other cases, HSP70, HSP90 and gp96 have increased the immunogenicity of tumors by increasing the synthesis of tumor antigens that can be recognized by the T cells. 40, 41 The significance of these HSPs is that as the tumor cell is being attacked, the cell synthesizes replacement proteins for those damaged ones. These newly synthesized proteins would also likely include potential antigenic peptides. HSPs act as chaperones, which can bind the antigenic peptides in a more permissive manner than peptides binding to MHC molecules. 40, 41 Once the tumor cell releases these peptide/HSP complexes, the host's antigen-presenting cells (APC), both dendritic cells and macrophages, can take up these antigens via the CD91 receptor. 42 Peptides complexed to HSPs stimulate immunity better against the antigen than when the antigenic peptide is not complexed to the HSP. HSP70 and gp96 have also been reported to enhance dendritic cell maturation. 30, 43 HSP70 also acts as a cytokine, which stimulates tumor necrosis factor, IL-1 and IL-6 production from CD14+monocytes, 44 which includes the immature dendritic cells. Thus, we speculate that one of the mechanisms through which living mM-CSF transfected cells stimulate antitumor immunity may be through the production of the HSPs, which activates the local APCs into becoming better antigen-presenting cells.
One of the difficulties of immunogene therapy based on developing an autologous vaccine is the difficulty of establishing glioma cell lines from each patient. 45, 46 Earlypassage human gliomas grow much slower than the established human glioma cell lines. It may take months to establish the glioma tumor cell lines. Next it is necessary to transfect the tumor cells, so that they express mM-CSF and to select the most appropriate clones for immunotherapy. In many cases, the length of the time necessary to do this entire procedure may exceed the lifespan of some patients, since the recurrence of the glioma may occur within a few months of the initial resection. One possible solution to this problem of lack of time is to use allogeneic tumor cells instead of using autologous tumor cells as the sources of the vaccine.
We found that in the rat T9 glioma model that immunization using living mM-CSF-expressing T9-C2 cells produced cross-protective immunity against the rechallenge of the syngeneic F98 and RT-2 gliomas. 24 This unique cross-protective immunity suggests that we can develop an allogeneic tumor vaccine composed of either a single glioma cell line or a pool of human glioma cells engineered to express high levels of mM-CSF to immunize other HLA-matched glioma patients. For safety precautions, these mM-CSF-transfected gliomas would also be genetically engineered with either thymidine kinase or cytidine deaminase suicide genes. Since the living mM-CSF-transfected glioma cells that are being killed via paraptosis do express HSPs, it may be possible to immunize patients with other MHC haplotypes different from the vaccines' MHC composition. HSPs complexed with antigenic peptides can produce immunity in individuals with different MHC haplotypes in a process called ''cross-presentation''. 47, 48 Thus, theoretically an allogeneic mM-CSF tumor vaccine may work in patients, if HSPs can cross-present tumor antigens. Studies are now ongoing in anti-asialo GM1-treated immunodeficient mice reconstituted with HLA-A2-matched PBMCs to prove that MG-2F11 cells can elicit a human immune response against the parental U251MG tumor. Our second aim is to determine whether cross-presentation against different human gliomas can be accomplished using different MHC-matched individuals and their gliomas using mM-CSF-transduced MG-2F11 cells.
